NIIMBL Aims To Help Manufacturers Perfect Next-Generation COVID-19 Vaccines
Executive Summary
Public-private partnership could help coronavirus vaccine developers increase thermal stability, strengthen potency assays and fine-tune adventitious agent testing, among other things.
You may also be interested in...
The Quality Lowdown: COVID-19's Pressures On Drug Quality
Demand surges, supply surges and investigator travel restrictions are forcing FDA to adopt less restrictive regulatory approaches during the pandemic.
Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.
US FDA ‘Brainstorms’ For Ways To Resume Pre-Pandemic Inspection Cadence
The FDA's drug inspections director discusses trends and challenges in remarks at a Georgia GMP conference, while declining to share specific ideas generated in last week’s agency brainstorming session.